Zai Lab to Present New PRIME Subgroup Analysis for Niraparib in Ovarian Cancer at 2022 ASCO Annual Conference
globenewswire.com
news
2022-05-31 00:00:00

Presentation features a new subgroup analysis of the Phase 3 PRIME study exploring the efficacy of niraparib maintenance therapy for patients in China with advanced ovarian cancer based on their response to first-line platinum-based chemotherapy Results showed a significant extension of progression-free survival compared with placebo, regardless of the response status to prior platinum-based chemotherapy SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced the presentation of a new subgroup data analysis from the Phase 3 PRIME study (NCT03709316) for niraparib in women in China with ovarian cancer at the upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 3-7, 2022.
